It appears to the Securities and Exchange Commission (the “Commission”) that the public interest and the protection of investors require a suspension in the trading of the securities of WPD Pharmaceuticals, Inc. (“WPD” or “the Company”) (CIK No. 0001798073) because of questions regarding the accuracy and adequacy of information in the marketplace about the Company and its securities. Those questions relate to, among other things, statements made by WPD and others, in a press release on April 9, and in other statements on March 19, March 20, and April 13 concerning the company’s business, including the status of development of a drug candidate labeled WP1122 for potential application to COVID-19, and the ability to expedite regulatory approval of any such treatment.

WPD is a British Columbia corporation whose principal place of business is listed as Vancouver, British Columbia. The Company’s common stock is quoted on OTC Link (previously Pink Sheets), operated by OTC Markets Group Inc., under the symbol WCOTF. As of April 20, 2020, WPD’s common stock had six market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed Company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on May 4, 2020, through 11:59 p.m. EDT on May 15, 2020.

By the Commission.

Vanessa A. Countryman
Secretary